secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001193125-22-218004
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica Q2 net loss $10.2M; plans VP-102 NDA resubmission in Q1 2023
--------------------------------------------------------------------

- Q2 2022 net loss $10.2M ($0.37 GAAP EPS); non-GAAP net loss $8.8M ($0.32/share).
- License revenue $0.2M from Torii; R&D $4.2M, G&A $5.2M.
- Held Type A FDA meeting; began working with Piramal for VP-102 bulk solution.
- Raised $28.5M gross in July 2022 public offering at $2.10/share.
- Cash, equivalents, marketable securities, restricted cash $54.4M as of June 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312522218004/0001193125-22-218004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312522218004/d358754d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-218004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer